ESTRO 2025 - Abstract Book

S1750

Clinical – Upper GI

ESTRO 2025

Clinical Oncology, Clatterbridge Cancer Centre, Liverpool, United Kingdom

Purpose/Objective: 1 In United Kingdom a combination of cisplatin, 5-FU and radiotherapy with 50 Gy in 25 fractions is the standard of care. 2 The CROSS trial showed that concurrent weekly carboplatin and paclitaxel with radiotherapy improved survival in patients receiving neoadjuvant treatment. 3 For patients with co-morbidities and reduced performance status, weekly carboplatin and paclitaxel are often used concurrently with radiotherapy given their better tolerability. We retrospectively analysed outcomes in patients receiving definitive chemo-radiotherapy with carboplatin and paclitaxel for oesophageal cancer over 2 years in Clatterbridge Cancer Centre. Material/Methods: Overall survival and acute toxicity data were collected from patients diagnosed with oesophageal cancer between 2019 and 2021 who were treated with 5 cycles of weekly carboplatin, paclitaxel and radiotherapy dose of 50 Gy in 25 fractions. VMAT technique was employed and 4D scans were utilised for lower oesophageal tumours. Retrospective analysis of data was done from electronic databases and individual patient records. Results: 59 patients diagnosed with Oesophageal cancer from January 2019 to December 2021 were treated and followed up for 2 years. 49% had adenocarcinoma and 49% had squamous cell carcinoma where 93% of the tumours were located in the lower and middle oesophagus. 83% of patients had a performance status of 0 or 1 and 17% had PS 2. 56% of the population completed five cycles of chemotherapy while only one person did not complete their radiotherapy regimen. The most common toxicity of any grade were esophagitis (74%), fatigue (61%), nausea (33%), Neutropenia (27%), followed by peripheral neuropathy (5%). Grade 3 and higher toxicities included Neutropenia (18%), febrile neutropenia (8%), Esophagitis (6%) and fatigue (5%). Radiological complete response and partial response were achieved in 13% and 40% of patients respectively. At 2 years follow-up, 42% had no recurrence, while local recurrence and distant recurrence were observed in 27% and 35% of the population. The most common sites of distant metastasis included lung, liver and bones. Median overall survival was 23 months. One year and two years overall survival rates were 67.8% and 45.8%. Univariate Analysis found no association between OS and sample variables.